Global Male Infertility Market, 2021-2027

January 2022 | 68 pages | ID: GECC0547CD35EN
Gen Consulting Company

Abstracts

Male infertility is any health issue in a man that lowers the chances of his female partner getting pregnant. Infertility can be caused by low sperm production, abnormal sperm function or blockages that prevent the delivery of sperm. Gen Consulting Company predicts global male infertility market will grow from USD 2,355 million in 2020 to USD 3,292 million by 2027, achieving a CAGR of 4.9 percent, according to the latest edition of the Global Male Infertility Market Report.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global male infertility market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments.

The male infertility market is segmented on the basis of testing method, treatment, and region. The male infertility market is segmented as below:

By testing method:

• computer assisted semen analysis
• DNA fragmentation technique
• microscopic examination
• oxidative stress analysis
• sperm agglutination
• sperm penetration assay
• others

By treatment:

• assisted reproductive technology
• medication

By region:

• Asia Pacific
• Europe
• North America
• Rest of the World (RoW)

The report also provides analysis of the key companies of the industry and their detailed company profiles including Aytu Biopharma, Inc., Bayer AG, CinnaGen Inc., EMD Serono, Inc., Endo International plc, Sandstone Diagnostics, Inc., Theramex HQ UK Limited, Vitrolife AB, among others.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period

This research report provides analysis for each segment from 2017 to 2027 considering 2020 to be the base year.

Scope of the Report

• To analyze and forecast the market size of the global male infertility market.
• To classify and forecast the global male infertility market based on testing method, treatment, and region.
• To identify drivers and challenges for the global male infertility market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global male infertility market.
• To identify and analyze the profile of leading players operating in the global male infertility market.

Why Choose This Report

• Gain a reliable outlook of the global male infertility market forecasts from 2021 to 2027 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

1.1 Market definition
1.2 Key benefits
1.3 Market segment

PART 2. METHODOLOGY

2.1 Primary
2.2 Secondary

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

4.1 Introduction
4.2 Market dynamics
  4.2.1 Drivers
  4.2.2 Restraints

PART 5. GLOBAL MARKET FOR MALE INFERTILITY BY TESTING METHOD

5.1 Computer assisted semen analysis
  5.1.1 Market size and forecast
5.2 DNA fragmentation technique
  5.2.1 Market size and forecast
5.3 Microscopic examination
  5.3.1 Market size and forecast
5.4 Oxidative stress analysis
  5.4.1 Market size and forecast
5.5 Sperm agglutination
  5.5.1 Market size and forecast
5.6 Sperm penetration assay
  5.6.1 Market size and forecast
5.7 Others
  5.7.1 Market size and forecast

PART 6. GLOBAL MARKET FOR MALE INFERTILITY BY TREATMENT

6.1 Assisted reproductive technology
  6.1.1 Market size and forecast
6.2 Medication
  6.2.1 Market size and forecast

PART 7. GLOBAL MARKET FOR MALE INFERTILITY BY REGION

7.1 Asia Pacific
  7.1.1 Market size and forecast
7.2 Europe
  7.2.1 Market size and forecast
7.3 North America
  7.3.1 Market size and forecast
7.4 Rest of the World (RoW)
  7.4.1 Market size and forecast

PART 8. KEY COMPETITOR PROFILES

8.1 Aytu Biopharma, Inc.
8.2 Bayer AG
8.3 CinnaGen Inc.
8.4 EMD Serono, Inc.
8.5 Endo International plc
8.6 Sandstone Diagnostics, Inc.
8.7 Theramex HQ UK Limited
8.8 Vitrolife AB
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

DISCLAIMER

ABOUT GEN CONSULTING COMPANY